Delving into the Latest Updates on Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Genetically engineered subunit vaccine

Synonyms

Convacell

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19COVID-19 respiratory infection

Inactive Indication-

Originator Organization

St. Petersburg Research Institute of Vaccines and Sera

Active Organization

St. Petersburg Research Institute of Vaccines and Sera

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

RU (18 Mar 2022),

COVID-19

Regulation-

Login to view timeline

The goal of this clinical trial is to assess the immunogenicity, efficacy and safety of the Convacell vaccine in healthy adult volunteers aged 18 years and older. The main questions it aims to answer are:
To assess the immunogenicity and safety of single and double dose intramuscular administration of the Convacell vaccine;
To assess the epidemiological effectiveness of the Convacell vaccine in the prevention of SARS-CoV-2 infection and development of severe COVID-19 compared with placebo when single or double intramuscular injection.

Start Date24 Oct 2022

Sponsor / Collaborator

St. Petersburg Research Institute of Vaccines and Sera

NCT05156723

/ CompletedPhase 1/2IIT

A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 Years

A two-stage trial will involve healthy volunteers. The first stage is open trial, and the second stage is a double-blind trial with randomization of volunteers into three groups. At stage I of the trial, the maximum number of screened healthy volunteers will be 30 of which 20 men aged 18 to over 60 years. At stage II of the trial, the maximum number of screened healthy volunteers will be 150, of which 135 men and women aged 18 to over 60 years eligible according to the inclusion and exclusion criteria are planned to be included and randomized to collect data that will be used for the subsequent safety and immunogenicity assessment. The enrollment of volunteers at stage II will be competitive.

Start Date19 Jul 2021

Sponsor / Collaborator

St. Petersburg Research Institute of Vaccines and Sera

100 Clinical Results associated with Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera)

Login to view more data

100 Translational Medicine associated with Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera)

Login to view more data

100 Patents (Medical) associated with Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera)

Login to view more data

98

Literatures (Medical) associated with Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera)

01 Feb 2025·Poultry Science

Vaccination with formulations targeting Eimeria maxima and Clostridium perfringens conferred comprehensive protection using a dual-infection challenge model of necrotic enteritis

Article

Author: Xu, Lixin ; Yuan, Yue ; Yuan, Cheng ; Yan, Ruofeng ; Li, Charles ; Zhang, Qingzheng ; Li, Xiangrui ; Pu, Xianglin ; Lu, Mingmin ; Song, Xiaokai

With increasing regulations restricting antibiotic use in animal feed, the need for alternative strategies to prevent and manage necrotic enteritis (NE) has become imperative. As a result, developing effective vaccines has emerged as a top priority for broiler chicken health management. Coccidial infections are a well-established predisposing factor for NE, underscoring the importance of controlling coccidiosis to help mitigate NE outbreaks. This research aimed to investigate the protective efficacy of vaccine preparations containing Eimeria maxima elongation factor-1α and a multicomponent antigen cocktail of Clostridium perfringens, including a single collagen adhesion protein (CpCna) and two chimeric proteins: CpNA (NetB-Alpha-toxin) and CpFZ (Fructose-1,6-bisphosphate aldolase-Zinc metalloprotease). Two vaccine preparations-recombinant subunit vaccines and DNA vaccines-were developed to assess their immunoprotective effects, determined by relative body weight gain rate, lesion scores, survival rates, and antigen-specific IgY levels using a dual-infection NE challenge model involving E. maxima and C. perfringens. Broilers were administered two subcutaneous immunizations with either adjuvanted proteins or eukaryotic expression plasmids on Days 7 and 17. Chickens vaccinated with the five antigens exhibited significantly higher serum antigen-specific IgY levels, improved weight gains, zero mortality, and reduced lesion scores following the lethal dual-infection challenge. These results indicated that vaccine preparations targeting both C. perfringens and E. maxima represent a promising approach for controlling and preventing coccidiosis-induced NE in chickens.

31 Dec 2024·Human Vaccines & Immunotherapeutics

Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice

Article

Author: Xie, Ying ; Bao, Chunting ; Wang, Jiahao ; Li, Shuyan ; Nie, Jiaojiao ; Li, Changgui ; Yang, Huijie ; Quan, Yaru

Mucosal immunity plays a crucial role in combating and controlling the spread of highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant subunit vaccines have shown safety and efficacy in clinical trials, but further investigation is necessary to evaluate their feasibility as mucosal vaccines. This study developed a SARS-CoV-2 mucosal vaccine using spike (S) proteins from a prototype strain and the omicron variant, along with a cationic chitosan adjuvant, and systematically evaluated its immunogenicity after both primary and booster immunization in mice. Primary immunization through intraperitoneal and intranasal administration of the S protein elicited cross-reactive antibodies against prototype strains, as well as delta and omicron variants, with particularly strong effects observed after mucosal vaccination. In the context of booster immunization following primary immunization with inactivated vaccines, the omicron-based S protein mucosal vaccine resulted in a broader and more robust neutralizing antibody response in both serum and respiratory mucosa compared to the prototype vaccine, enhancing protection against different variants. These findings indicate that mucosal vaccination with the S protein has the potential to trigger a broader and stronger antibody response during primary and booster immunization, making it a promising strategy against respiratory pathogens.

01 Dec 2024·Vaccine

Development and characterization of HCMV recombinant subunit vaccines based on T-cell epitopes

Article

Author: Zhang, Shuyun ; Wang, Bin ; Liu, Wenxuan ; Liu, Fengjun ; Li, Jun ; Li, Zonghui ; Yu, Meng ; Jiang, Shasha ; Li, Xu ; Wang, Yunyang

Human cytomegalovirus (HCMV), a ubiquitous β-herpes virus, mostly causes asymptomatic infections in adults with healthy immune systems. Due to immunosuppressive therapy, solid organ transplantation (SOT) recipients are at increased risk of HCMV infection. In recent years, the interdisciplinary, filed of immunoinformatics, based on computer science, and modern immunology, has emerged. In this study, we designed three types of recombinant subunit vaccines, which are expressed by the E. coli BL21 strain according to immunoinformatics prediction. Subsequently, we evaluated the innate and cellular immune responses of recombinant subunit vaccines in vivo and/or in vitro. Flow cytometry analysis, revealed that recombinant subunit vaccines enhanced both innate and cellular immune responses in vivo and/or in vitro. We also found that the novel herb adjuvant hesperetin (HES) increased memory T cell inflation. Overall, we developed three types of recombinant subunit vaccines based on HCMV antigen fragments containing multiple T-cell epitopes and assessed the innate and cellular immune responses in vivo and/or in vitro.

100 Deals associated with Subunit recombinant vaccine(St. Petersburg Research Institute of Vaccines and Sera)

Login to view more data